SOURCE: CannaPharmaRx, Inc.

CannaPharmaRx, Inc. Logo

June 11, 2015 09:53 ET

CannaPharmaRx to Be a Featured Presenter at the Viridian Cannabis Investor Conference

CARNEYS POINT, NJ--(Marketwired - June 11, 2015) - CannaPharmaRx, Inc. (OTCQB: CPMD), a leader in the research, development, and commercialization of cannabinoid-based drug products, announced today that it will be a featured presenter at the Viridian Capital Cannabis Investor Conference, New York City's first cannabis investment seminar. The conference will be held on June 18, 2015 at the Jacob Javits Center in New York City. This invite-only event is being hosted by Viridian Capital Advisors, the first investment banking firm dedicated to the Cannabis market, in partnership with the Cannabis World Congress & Business Exposition, the premier Cannabis business conference on the East Coast.

The event, entitled, "Investing in the Emerging Cannabis Industry While Managing Risk," will present the opportunities and risks unique to the Cannabis industry. Industry CEOs, entrepreneurs and government/law enforcement officials will speak about the critical topics investors should consider when investing in this market.

Gerry Crocker, CannaPharmaRx's CEO, commented, "CannaPharmaRx has put together what we believe is the most experienced management team in the emerging cannabinoid R&D marketplace. We're excited to present our team and our strategy to the investment community in New York City."

Scott Greiper, President of Viridian Capital Advisors, remarked, "Gerry Crocker is leading a team that has launched over 100 molecules for major pharmaceutical companies, managed distribution channels for $9 billion in annual sales, and raised over $750 million in capital for startup pharmaceutical companies. We're excited to have CannaPharmaRx as our client and as a presenter at our event."

About CannaPharmaRx, Inc.
CannaPharmaRx, Inc. is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. Cannabinoids are a class of chemicals that, once ingested, are active in humans and animals through the "endocannabinoid system" -- one of the most widely expressed system of receptors in the human body. CannaPharmaRx is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: insomnia, neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology. For more information, please visit

About Viridian Capital Advisors, LLC
Viridian Capital Advisors, LLC is the first Wall Street investment bank and advisory platform dedicated to the Cannabis market. We are a specialized boutique banking and strategic advisory firm that provides research, investment banking, investor relations and corporate development services to emerging growth companies in the Cannabis sector. Our banking practice, through broker-dealer Pickwick Capital Partners, provides capital and M&A to fund the growth of our clients, while our advisory practice helps to position and build their business. Leveraging our team's decades of high level operating and transactional experience on Wall Street, in industry and in the government, we provide flexible comprehensive strategic and financial solutions that assist Cannabis enterprises in realizing their full potential. For more information, please visit

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend" among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that matters discussed in this press release will be completed or successful. CannaPharmaRx does not undertake any obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's Annual Report on Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

Contact Information